haematology
Blood cancers

Australian study provides insight into long-term efficacy of venetoclax in relapsed CLL


An extended follow-up on pooled data from four early-phase clinical trials of venetoclax in patients with previously treated CLL or small lymphocytic lymphoma has confirmed which patients are most likely to do well. The study, comprising 436 patients who had been heavily treated with a median of three prior therapies, found a three-year progression free ...

Already a member?

Enter your email to keep reading.


OR